Primary and Secondary Prevention of CAD: A Review

Abstract

Coronary artery disease is the leading cause of death in both men and women, yet adequate control of risk factors can largely reduce the incidence and recurrence of cardiac events. In this review, we discuss various life style and pharmacological measures for both the primary and secondary prevention of coronary artery disease. With a clear understanding of management options, health care providers have an excellent opportunity to educate patients and ameliorate a significant burden of morbidity and mortality.

Keywords

atherosclerosis - coronary artery - hypercholesterolemia - hypertension - myocardial infarction - prevention - aspirin

Publikationsverlauf

Artikel online veröffentlicht:
24. Dezember 2021

• References

• 1 World Health Organization. The top 10 causes of death. 2018 . Retrieved from https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
• 2 World Health Organization. Cardiovascular diseases. 2020 . Retrieved from https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1
• 3 Centers for Disease Control and Prevention. Heart disease facts. 2020 . Retrieved from https://www.cdc.gov/heartdisease/facts.htm
• 4 Arnett DK, Blumenthal RS, Albert MA. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2019; 140 (11) e596-e646
• 5 Khera R, Pandey A, Ayers CR. et al. Performance of the pooled cohort equations to estimate atherosclerotic cardiovascular disease risk by body mass index. JAMA Netw Open 2020; 3 (10) e2023242
• 6 Rodriguez F, Chung S, Blum MR, Coulet A, Basu S, Palaniappan LP. Atherosclerotic cardiovascular disease risk prediction in disaggregated Asian and Hispanic subgroups using electronic health records. J Am Heart Assoc 2019; 8 (14) e011874
• 7 Rifai MA, Cainzos-Achirica M, Kanaya AM. et al. Discordance between 10-year cardiovascular risk estimates using the ACC/AHA 2013 estimator and coronary artery calcium in individuals from 5 racial/ethic groups: comparing MASALA and MESA. Atherosclerosis 2018; 279: 122-129
• 8 Triant VA, Perez J, Regan S. et al. Cardiovascular risk prediction functions underestimate risk in HIV infection. Circulation 2018; 137 (21) 2203-2214
• 9 Addison D, Spahillari A, Rokicki A. The pooled cohort risk equation markedly underestimates the risk of atherosclerotic cardiovascular events after radiation therapy. J Am Coll Cardiol 2018; 71 (Suppl. 21) A1862
• 10 Kondo T, Nakano Y, Adachi S, Murohara T. Effects of tobacco smoking on cardiovascular disease. Circ J 2019; 83 (10) 1980-1985
• 11 Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43 (10) 1731-1737
• 12 Prochaska JJ, Benowitz NL. Smoking cessation and the cardiovascular patient. Curr Opin Cardiol 2015; 30 (05) 506-511
• 13 Suissa K, Larivière J, Eisenberg MJ. et al. Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017; 10 (01) e002458
• 14 McBride CM, Emmons KM, Lipkus IM. Understanding the potential of teachable moments: the case of smoking cessation. Health Educ Res 2003; 18 (02) 156-170
• 15 Windle SBDP, Dehghani P, Roy N. et al. EVITA Investigators. Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital. CMAJ 2018; 190 (12) E347-E354
• 16 Benowitz NL, Burbank AD. Cardiovascular toxicity of nicotine: implications for electronic cigarette use. Trends Cardiovasc Med 2016; 26 (06) 515-523
• 17 Joseph AM, Norman SM, Ferry LH. et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335 (24) 1792-1798
• 18 Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005; 95 (08) 976-978
• 19 Eisenberg MJ, Grandi SM, Gervais A. et al. ZESCA Investigators. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol 2013; 61 (05) 524-532
• 20 Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ. Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2016; 5 (02) 5
• 21 Brandhorst S, Longo VD. Dietary restrictions and nutrition in the prevention and treatment of cardiovascular disease. Circ Res 2019; 124 (06) 952-965
• 22 Eckel RH, Jakicic JM, Ard JD. et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014; 129 (25, Suppl 2): [Erratum in: Circulation 2014;129(25 Suppl 2):S100–S101. Erratum in: Circulation 2015;131(4):e326] S76-S99
• 23 Budhathoki S, Sawada N, Iwasaki M. et al. Japan Public Health Center–based Prospective Study Group. Association of animal and plant protein intake with all-cause and cause-specific mortality in a Japanese cohort. JAMA Intern Med 2019; 179 (11) 1509-1518
• 24 Anand SS, Hawkes C, de Souza RJ. et al. Food consumption and its impact on cardiovascular disease: importance of solutions focused on the globalized food system: a report from the workshop convened by the World Heart Federation. J Am Coll Cardiol 2015; 66 (14) 1590-1614
• 25 Shikany JM, Safford MM, Newby PK, Durant RW, Brown TM, Judd SE. Southern dietary pattern is associated with hazard of acute coronary heart disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Circulation 2015; 132 (09) 804-814
• 26 Dias JM, Cisneros L, Ferreira PH. et al. Hydrotherapy improves pain and function in older women with knee osteoarthritis: a randomized controlled trial. Braz J Phys Ther 2017; 21 (06) 449-456
• 27 Hsu S, Ton VK, Dominique Ashen M. et al. A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. Clin Cardiol 2013; 36 (07) 383-393
• 28 Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365 (9455): 217-223
• 29 Lawes CMM, Bennett DA, Lewington S, Rodgers A. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med 2002; 2 (04) 355-368
• 30 Diaz KM, Shimbo D. Physical activity and the prevention of hypertension. Curr Hypertens Rep 2013; 15 (06) 659-668
• 31 Gelber RP, Gaziano JM, Manson JE, Buring JE, Sesso HD. A prospective study of body mass index and the risk of developing hypertension in men. Am J Hypertens 2007; 20 (04) 370-377
• 32 Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA 2009; 302 (04) 401-411
• 33 Jennings GL. A new guideline on treatment of hypertension in those with coronary artery disease: scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension about treatment of hypertension in patients with coronary artery disease. Heart Lung Circ 2015; 24 (11) 1037-1040
• 34 Rosendorff C, Black HR, Cannon CP. et al. American Heart Association Council for High Blood Pressure Research, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115 (21) 2761-2788
• 35 Yusuf S, Pitt B, Davis CE, Hood Jr WB, Cohn JN. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327 (10) 685-691
• 36 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342 (03) 145-153
• 37 Pitt B, Zannad F, Remme WJ. et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341 (10) 709-717
• 38 Hajar R. Diabetes as “coronary artery disease risk equivalent”: a historical perspective. Heart Views 2017; 18 (01) 34-37
• 39 Burger KNJ, Beulens JWJ, van der Schouw YT. et al. Dietary fiber, carbohydrate quality and quantity, and mortality risk of individuals with diabetes mellitus. PLoS One 2012; 7 (08) e43127
• 40 Gummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab 2017; 19 (09) 1295-1305
• 41 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352 (9131): 854-865
• 42 Zweck E, Roden M. GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?. Lancet Diabetes Endocrinol 2019; 7 (02) 89-90
• 43 Krumholz HM. Cardiovascular effects of SGLT2 inhibitors. N Engl J Watch 2018 Nov 10 [e-pub]. Retrieved from https://www.jwatch.org/na47925/2018/11/10/cardiovascular-effects-sglt2-inhibitors
• 44 McMurray JJV, Solomon SD, Inzucchi SE. et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381 (21) 1995-2008
• 45 Anker SD, Butler J, Filippatos G. et al. EMPEROR-Reduced Trial Committees and Investigators. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced trial. Circulation 2021; 143 (04) 337-349
• 46 Saeed A, Mehta LS. Statin Therapy in Older Adults for Primary Prevention of Atherosclerotic Cardiovascular Disease: The Balancing Act. American College of Cardiology 2020 Oct 01 [e-pub]. Retricved from https://www.acc.org/latest-in-cardiology/articles/2020/10/01/11/39/statin-therapy-in-order-adults-for-primary-prevention-of-atherosclerotic-cv-disease
• 47 Grundy SM, Stone NJ, Bailey AL. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139 (25) e1082-e1143
• 48 Baigent C, Blackwell L, Emberson J. et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376 (9753): 1670-1681
• 49 Cannon CP, Braunwald E, McCabe CH. et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350 (15) 1495-1504
• 50 LaRosa JC, Grundy SM, Waters DD. et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14) 1425-1435
• 51 Ornelas A, Zacharias-Millward N, Menter DG. et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev 2017; 36 (02) 289-303
• 52 Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321 (03) 129-135
• 53 de Gaetano G. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357 (9250): [Erratum in: Lancet 2001;357(9262):1134] 89-95
• 54 Ogawa H, Nakayama M, Morimoto T. et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300 (18) 2134-2141 [Erratum in: JAMA 2009;301(18):1882. Erratum in: JAMA 2012;308(18):1861]
• 55 Belch J, MacCuish A, Campbell I. et al. Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840
• 56 Fowkes FG, Price JF, Stewart MC. et al. Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303 (09) 841-848
• 57 Ikeda Y, Shimada K, Teramoto T. et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312 (23) 2510-2520
• 58 Bowman L, Mafham M, Wallendszus K. et al. ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379 (16) 1529-1539
• 59 McNeil JJ, Wolfe R, Woods RL. et al. ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018; 379 (16) 1509-1518
• 60 Gaziano JM, Brotons C, Coppolecchia R. et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392 (10152): 1036-1046
• 61 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2 (8607): 349-360
• 62 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. [published correction appears in BMJ. 2002;324:141]. BMJ 2002; 324 (7329): 71-86
• 63 Smith Jr SC, Benjamin EJ, Bonow RO. et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124 (22) 2458-2473 [Erratum in: Circulation 2015;131(15):e408]
• 64 Souza PR, Marques RM, Gomez EA. et al. Enriched marine oil supplements increase peripheral blood specialized pro-resolving mediators concentrations and reprogram host immune responses: a randomized double-blind placebo-controlled study. Circ Res 2020; 126 (01) 75-90
• 65 Aung T, Halsey J, Kromhout D. et al. Omega-3 Treatment Trialists' Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol 2018; 3 (03) 225-234
• 66 Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants. J Am Heart Assoc 2019; 8 (19) e013543
• 67 Bhatt DL, Steg PG, Miller M. et al. REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380 (01) 11-22
• 68 U.S. Food and Drug Administration. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups [Press release]. December 13, 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups
• 69 Wang TJ, Pencina MJ, Booth SL. et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117 (04) 503-511
• 70 Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168 (11) 1174-1180
• 71 D'Ambrosio D, Cippitelli M, Cocciolo MG. et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101 (01) 252-262
• 72 Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986; 119 (01) 84-90
• 73 Zittermann A, Koerfer R. Protective and toxic effects of vitamin D on vascular calcification: clinical implications. Mol Aspects Med 2008; 29 (06) 423-432
• 74 Manson JE, Cook NR, Lee IM. et al. VITAL Research Group. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 2019; 380 (01) 33-44
• 75 Collaboration H. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998; 316 (7135): 894-898
• 76 Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB. Folic acid supplementation and the risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. J Am Heart Assoc 2016; 5 (08) e003768
• 77 Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012; 125 (09) 882-7.e1
• 78 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19) 2486-2497
• 79 Ridker PM, Buring JE, Rifai N. et al. Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women. JAMA 2007; 297: 611-619
• 80 Hippisley-Cox J, Coupland C, Brindle P. Development and Validation of QRISK3 Risk Prediction Algorithms to Estimate Future Risk of Cardiovascular Disease: Prospective Cohort Study. BMJ 2017; 357: j2099
• 81 Goff Jr DC, Lloyd-Jones DM, Bennett G. et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 ;(suppl 2): S49-73
• 82 Barua RS, Rigotti NA, Benowitz NL. et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2018; 72 (25) 3332-3365
• 83 Arnett DK, Blumenthal RS, Albert MA. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A report of the American College of Cardiology/American Heart Association on Clinical Practice Guidelines. Circulation 2019; 140 (11) e596-646
• 84 Stone NJ, Robinson JG, Lichtenstein AH. et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 1 (63) 2889-2934
• 85 Smith Jr SC, Benjamin EJ, Bonow RO. et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Circulation 2011; 124: 2458-2473